Seprafilm

03/01/2002 - "Our study suggests that Seprafilm does not affect tumor metastasis. "
02/01/2004 - "Therefore, if Seprafilm were attached to the injured peritoneum after laparoscopic surgery for cancer patients, it might reduce port site metastasis."
03/01/2002 - "Further studies in other animal models and ultimately, in humans are required to unambiguously understand the safety of Seprafilm and other biomaterials in cancer patients."
09/01/2008 - "Our results suggest that Seprafilm does not promote intraperitoneal tumor growth, especially compared with Vicryl mesh."
09/01/2008 - "In contrast, only 64 percent of mice in the Seprafilm group developed tumors (P = 0.024), and these tumors were smaller than those in the sham group; (Seprafilm = 42 +/- 9 mg vs. sham = 82 +/- 17 mg; P = 0.05). "

01/01/2018 - "The objective of this study was to clarify the protective efficacy of Seprafilm against BO after laparoscopic surgery for colorectal cancer. "
10/01/2002 - "Seprafilm did not adversely affect the short-term recurrence rate after curative resection of colorectal cancer. "
10/01/2002 - "Seprafilm: a retrospective preliminary evaluation of the impact on short-term oncologic outcome in colorectal cancer."
03/01/2009 - "Seprafilm appears to be effective in preventing early postoperative intestinal obstruction and there was a trend for reduced intestinal obstruction after lower abdominal surgery for colorectal cancer."
03/01/2009 - "This study is a prospective randomized clinical trial to evaluate the clinical safety and the effect of a sodium hyaluronate-based bioresorbable membrane (Seprafilm; Genzyme, Cambridge, MA, USA) for reducing adhesive intestinal obstruction after colorectal cancer surgery. "

09/01/2012 - "However, laparoscopic examinations in these 2 patients revealed only gel-like hydrated Seprafilm without evidence of infection. "
01/01/2011 - "Seprafilm may improve the safety of VP shunt reinsertion and preserve the function of the reinserted VP shunt after VP shunt malfunction with infection."
01/01/2010 - "The incidence of surgical infection showed no significant difference between the Seprafilm group (3.6%) and the control group (6.7%). "
04/01/2021 - "Current smoking, use of seprafilm, CRP level on POD2 and vaginal cuff hematoma were identified as significant risk factors of vaginal cuff infection in the 30 days after surgery in Japanese women who underwent TLH for benign indications."
04/01/2021 - "In multivariate analysis, current smoking, use of seprafilm, CRP level on POD2 and vaginal cuff hematoma were significantly associated with an increased risk of vaginal cuff infection. "

05/01/2001 - "During short-term follow-up in this nonprospective, nonrandomized study, limited placement of Seprafilm did not significantly reduce the need for surgical enterolysis for intestinal obstruction or significantly adversely affect the morbidity rate. "
03/01/2009 - "Five patients in the Seprafilm group experienced postoperative intestinal obstruction (2.7%) compared with 11 patients in the control group (4.6%) during the follow-up period; however, there was no statistical difference. "
03/01/2009 - "There were no differences in the incidence of complications between the two groups; however, the incidence of early postoperative intestinal obstruction was significantly less in the Seprafilm group than in the control group (2.7% vs 7.0%, respectively, p = 0.045). "
11/01/2007 - "Our systematic review and meta-analysis showed that Seprafilm could decrease abdominal adhesions after general surgery, which may benefit patients, but could not reduce postoperative intestinal obstruction. "
11/01/2007 - "The incidence of intestinal obstruction after abdominal surgery was not different between Seprafilm and control groups (OR 95%CI, 0.78-1.23; p = 0.84). "

08/01/2000 - "Seprafilm is highly effective in preventing adhesions to PPM. This effect was not diminished by the presence of visceral trauma and its resultant inflammatory response. "
05/01/2009 - "Retrospective case series of 4 consecutive patients with trap door orbital wall fractures secondary to blunt trauma with entrapped orbital soft tissue who underwent surgical repair with placement of Seprafilm implant in 2008. "
05/01/2008 - "Before closing the abdominal incision, 2 sheets of Seprafilm membrane were applied to the surface of the small intestine under the middle abdominal wound in the Seprafilm group. "
02/01/2004 - "Seprafilm protects peritoneal wounds by physically covering the injured peritoneum. "
10/01/2003 - "Patients received an average of 4.4 and as many as 10 Seprafilm adhesion barriers applied to organs and tissue surfaces that sustained direct surgical trauma and to suspected adhesiogenic surfaces. "